| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Vol. 54, Issue 2, 219-226, June 2002
Clinical Pharmacology Unit, University of Cambridge,
Centre for Clinical Investigation, Addenbrooke's Hospital,
Cambridge, United Kingdom
I. Introduction
II. Cloned Endothelin Receptors
III. Mammalian Splice Variants of EndothelinA and
EndothelinB Receptors
IV. Physiological Role of Receptors
V. Endogenous and Synthetic Agonists
VI. Radiolabeled Agonists
VII. Antagonists
VIII. Radiolabeled EndothelinA Selective Antagonists
IX. EndothelinB Selective Antagonists
X. EndothelinA/EndothelinB Antagonists
XI. Conclusions
Acknowledgments
References
In mammals, the endothelin (ET) family comprises three endogenous isoforms, ET-1, ET-2, and ET-3. ET-1 is the principal isoform in the human cardiovascular system and remains the most potent and long-lasting constrictor of human vessels discovered. In humans, endothelins mediate their actions via only two receptor types that have been cloned and classified as the ETA and ETB receptors in the first NC-IUPHAR (International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification) report on nomenclature in 1994. This report was compiled before the discovery of the majority of endothelin receptor antagonists (particularly nonpeptides) currently used in the characterization of receptors and now updated in the present review. Endothelin receptors continue to be classified according to their rank order of potency for the three endogenous isoforms of endothelin. A selective ETA receptor agonist has not been discovered, but highly selective antagonists include peptides (BQ123, cyclo-[D-Asp-L-Pro-D-Val-L-Leu-D-Trp-]; FR139317, N- [(hexahydro-1-azepinyl)carbonyl]L-Leu(1-Me)D-Trp-3 (2-pyridyl)-D-Ala) and the generally more potent nonpeptides, such as PD156707, SB234551, L754142, A127722, and TBC11251. Sarafotoxin S6c, BQ3020 ([Ala11,15]Ac-ET-1(6-21)), and IRL1620 [Suc-(Glu9, Ala11,15)-ET-1(8-21)] are widely used synthetic ETB receptor agonists. A limited number of peptide (BQ788) and nonpeptide (A192621) ETB antagonists have also been developed. They are generally less potent than ETA antagonists and display lower selectivity (usually only 1 to 2 orders of magnitude) for the ETB receptor. Radioligands highly selective for either ETA (125I-PD151242, 125I-PD164333, and 3H-BQ123) or ETB receptors (125I-BQ3020 and 125I-IRL1620) have further consolidated classification into only these two types, with no strong molecular or pharmacological evidence to support the existence of further receptors in mammals.
This article has been cited by other articles:
|
|
 |
|
  J. Dupuis and M. M. Hoeper Endothelin receptor antagonists in pulmonary arterial hypertension Eur. Respir. J., February 1, 2008; 31(2): 407 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Y. Lai, A. E. G. Persson, B. Bodin, O. Kallskog, A. Andersson, U. Pettersson, P. Hansell, and L. Jansson Endothelin-1 and pancreatic islet vasculature: studies in vivo and on isolated, vascularly perfused pancreatic islets Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1616 - E1623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hatae, N. Aksentijevich, H. W. Zemkova, K. Kretschmannova, M. Tomic, and S. S. Stojilkovic Cloning and Functional Identification of Novel Endothelin Receptor Type A Isoforms in Pituitary Mol. Endocrinol., May 1, 2007; 21(5): 1192 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N F Kelland and D J Webb Clinical trials of endothelin antagonists in heart failure: publication is good for the public health Heart, January 1, 2007; 93(1): 2 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Leiber, Y. Banno, and Z. Tanfin Exogenous sphingosine 1-phosphate and sphingosine kinase activated by endothelin-1 induced myometrial contraction through differential mechanisms Am J Physiol Cell Physiol, January 1, 2007; 292(1): C240 - C250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. C. Kopp, M. Z. Cicha, and L. A. Smith Differential effects of endothelin on activation of renal mechanosensory nerves: stimulatory in high-sodium diet and inhibitory in low-sodium diet Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1545 - R1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Kelland and D. J. Webb Clinical Trials of Endothelin Antagonists in Heart Failure: A Question of Dose? Experimental Biology and Medicine, June 1, 2006; 231(6): 696 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bras-Silva and A. F. Leite-Moreira Obligatory role of the endocardial endothelium in the increase of myocardial distensibility induced by endothelin-1. Experimental Biology and Medicine, June 1, 2006; 231(6): 876 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Thieme, C. Schimmat, G. Munzer, M. Boxberger, M. Fromm, N. Pfeiffer, and R. Rosenthal Endothelin Antagonism: Effects of FP Receptor Agonists Prostaglandin F2{alpha} and Fluprostenol on Trabecular Meshwork Contractility. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 938 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, M. Tong, S. Chinta, J. U. Raj, and Y. Gao Hypoxia-induced reactive oxygen species downregulate ETB receptor-mediated contraction of rat pulmonary arteries Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L570 - L578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. C. Fabricio, G. A. Rae, A. R. Zampronio, P. D'Orleans-Juste, and G. E. P. Souza Central endothelin ETB receptors mediate IL-1-dependent fever induced by preformed pyrogenic factor and corticotropin-releasing factor in the rat Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R164 - R171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wettschureck and S. Offermanns Mammalian G Proteins and Their Cell Type Specific Functions Physiol Rev, October 1, 2005; 85(4): 1159 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Lee, R. F. Gonzalez, C. J. Chapin, J. Busch, J. R. Fineman, and J. A. Gutierrez Nitric oxide decreases surfactant protein gene expression in primary cultures of type II pneumocytes Am J Physiol Lung Cell Mol Physiol, May 1, 2005; 288(5): L950 - L957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Leite-Moreira and C. Bras-Silva Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1194 - H1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Filippi, M. Marini, G.B. Vannelli, C. Crescioli, S. Granchi, L. Vignozzi, M. Luconi, P. Ferruzzi, A. Morelli, G. Forti, et al. Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum Mol. Hum. Reprod., December 1, 2003; 9(12): 765 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Boivin, D. Chevalier, L. R. Villeneuve, E. Rousseau, and B. G. Allen Functional Endothelin Receptors Are Present on Nuclei in Cardiac Ventricular Myocytes J. Biol. Chem., August 1, 2003; 278(31): 29153 - 29163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Granchi, G.B. Vannelli, L. Vignozzi, C. Crescioli, P. Ferruzzi, R. Mancina, M.C. Vinci, G. Forti, S. Filippi, M. Luconi, et al. Expression and regulation of endothelin-1 and its receptors in human penile smooth muscle cells Mol. Hum. Reprod., December 1, 2002; 8(12): 1053 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Maas, E. Schwedhelm, J. Albsmeier, and R. H Boger The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function Vascular Medicine, August 1, 2002; 7(3): 213 - 225. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
